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Abstract: 
 
Chondrosarcoma is the third most common primary bone cancer, requiring surgical 
resection. However, differentiation of low-grade chondrosarcoma (grade 1) from 
enchondroma that is benign and only requires regular follow-up is one of the most 
frequent diagnostic dilemmas facing orthopedic oncologists in clinical management. 
Although multiple techniques are applied to make the distinction, immunohistochemistry 
is an important ancillary technique, especially when a histopathological stain of 
specimen must be obtained in order to guarantee an accurate confirmation. Currently, 
no adequate immunohistochemical diagnostic protein biomarkers are available to 
distinguish low-grade chondrosarcoma from enchondroma. To discover novel protein 
biomarker candidates, a liquid chromatography-tandem mass spectrometry approach 
was applied to directly compare formalin-fixed, paraffin-embedded low-grade 
chondrosarcoma with enchondroma tissue samples. The proteomics analysis revealed 
17 protein biomarker candidates.  A principle was developed to prioritize the candidates 
using category and ranking. An algorithm, prioritization index of biomarker candidates 
for immunohistochemistry on tissue specimens (PIBIT), was developed to rank the 
candidates inside each category. Using the proteomics data and bioinformatics results, 
the PIBIT revealed periostin as a top candidate. Immunohistochemical staining of 
periostin in 23 low-grade chondrosarcoma and 31 enchondroma tissue specimens 
disclosed the specificity 87% and the sensitivity 70%. 
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1 Introduction 
 
Chondrosarcoma is the third most common primary bone cancer [1, 2]. Based on 
cellularity, nuclear atypia, and pleomorphism, chondrosarcoma is histologically 
classified into three grades [3], including low-grade (grade 1), intermediate grade (grade 
2), and high-grade (grade 3) [4]. Wide surgical resection is the most common treatment 
choice for chondrosarcoma [2]. Clinically, it is crucial to distinguish low-grade 
chondrosarcoma from its benign counterpart enchondroma, because enchondroma only 
requires regular follow-up [5]. 
Histologically, distinction of between a low-grade chondrosarcoma from a benign 
enchondroma relying solely on morphological features is difficult and even impossible in 
many cases for skilled pathologists because of their similar cytology, cellularity, and 
cartilaginous matrix [4, 6-8]. Therefore, correlative interpretation of histopathological 
features, x-ray imaging, computerized tomography, magnetic resonance imaging, 
clinical examination, and epidemiological information is currently used for making this 
distinction [5, 9]. Most often, however, a histopathological stain of specimen must be 
obtained in order to guarantee an accurate confirmation [5]. Therefore, 
immunohistochemistry is chosen to distinguish a low-grade chondrosarcoma from a 
benign enchondroma, because it has been proven to be one of the most important 
ancillary techniques.  
Currently, numerous proteins have been immunohistochemically tested to distinguish 
low-grade chondrosarcoma from enchondroma. However, many of them were carried 
out on a small number of cases (< 10). Among the proteins tested on ≥ 10 cases, only 
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12 proteins, ADAM28, CCND1, FERMT2, FOS, ILK, JUN, JUNB, MAPK3, MAPK9, 
PARVB, PTH1R, and RUNX2 [10-14], possess both sensitivity and specificity ≥ 50%. 
Only 3 of the 12 proteins, FERMT2, FOS, and MAPK3, have both sensitivity and 
specificity ≥ 70%. It is unlikely for a biomarker to achieve 100% sensitivity and 100% 
specificity. An ideal biomarker needs to have at least 90% sensitivity and 90% or more 
specificity [15]. Obviously, there are not enough promising candidates in the validation 
at a larger scale to distinguish low-grade chondrosarcoma from enchondroma. 
Moreover, the majority of the tested proteins were simply chosen because either they 
were reported to involve signaling pathways in other tumors [13] or they play an 
important role in cell motility, growth, survival, and ultimately carcinogenesis [12]. They 
were not chosen from the direct comparison of low-grade chondrosarcoma with 
enchondroma. 
To discover more meaningful protein candidates to meet the 90/90 standard, a global 
and high-throughput approach should be applied to directly compare low-grade 
chondrosarcoma with enchondroma. At present, genomics and proteomics have been 
used only in three and two publications to discover biomarker candidates for the 
differentiation, respectively [14, 16-19]. The only applied proteomic technique is two-
dimensional electrophoresis that has multiple limitations in proteome analysis [20]. Not 
surprisingly, just a few biomarker candidates have been discovered so far. On the 
contrary, a shotgun proteomics approach provides better profiling of proteins because of 
its sensitivity and high-throughput capability [21]. Therefore, a liquid chromatography-
tandem mass spectrometry (LC-MS/MS) approach should be pursued for the biomarker 
discovery. 
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The goals of the present study are to discover and validate protein biomarker 
candidates for immunohistochemical diagnosis to distinguish low-grade 
chondrosarcoma from enchondroma. In this study, formalin-fixed paraffin-embedded 
(FFPE) tissue samples of low-grade chondrosarcoma and enchondroma were analyzed 
using a quantitative LC-MS/MS approach. The FFPE samples were chosen because 
fresh-frozen tissues were not available. One of the discovered protein biomarker 
candidates was validated with immunohistochemistry. The results indicated that the 
entire workflow from discovery to validation performed remarkably well, significantly 
expanding the number of meaningful biomarker candidates reported in previous studies. 
Also, the results provided a very promising candidate for further validation at an even 
larger scale. 
 
2 Materials and methods 
 
2.1 Tissue blocks 
 
This study was approved by the Indiana University Institutional Review Board (IRB # 
1403932283). Two sets of FFPE tissue blocks of both low-grade chondrosarcoma and 
enchondroma were obtained from the Indiana University Health Pathology Laboratory. 
Case Set 1, used for the LC-MS/MS experiment, included five low-grade 
chondrosarcoma and five enchondroma samples from FFPE tissue blocks prepared 
between 2007 and 2013. Case Set 2, applied for immunohistochemical stain verification 
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of specific proteins, contained 23 low-grade chondrosarcoma and 31 enchondroma 
tissue specimens collected between 2000 and 2014.  
 
2.2 Materials 
 
Urea, DL-Dithiothreitol (DTT), triethylphosphine, iodoethanol, and ammonium 
bicarbonate (NH4HCO3) were purchased from Sigma-Aldrich (St. Louis, MO, USA). LC-
MS grade water (H2O), LC-MS grade 0.1% formic acid in acetonitrile (ACN), and 0.1% 
formic acid in water (H2O) were purchased from Burdick & Jackson (Muskegon, MI, 
USA). Modified sequencing grade porcine trypsin was obtained from Princeton 
Separations (Freehold, NJ, USA).  
 
2.3 Label-free analysis  
 
2.3.1 Protein extraction from the FFPE samples 
 
Protein extraction from the FFPE samples was performed according to an integrated 
procedure including deparaffinization, rehydration, cross-link reversion, and protein 
extraction [22]. Briefly, after an FFPE tissue block was cut into slices (5x2.5x1 mm, 
lengthxwidthxheight), visible paraffin was removed with a forceps. The slices were 
placed in a 2.0 mL collection tube and ten volumes (500 µL for 50 mg of tissue slices) of 
100 mM NH4HCO3 at pH 8.0 were added to the tube. The sample was incubated at 99 
°C for 30 min at 900 rpm on an Eppendorf Thermomixer to get the First Extraction. The 
 7 
 
tissue slices were homogenized, generating a milk-like solution. The solution was 
incubated at 99 °C for 60 min at 900 rpm on the Eppendorf Thermomixer to obtain the 
Second Extraction. The Third Extraction was carried out with incubation at 99 °C for 60 
min at 900 rpm. The three extractions were pooled and then stored at -80 °C until 
analysis. Protein concentration was determined by the Bradford Protein Assay using 
Bio-Rad protein assay dye reagent concentrate [23].  
 
2.3.2 Protein reduction, alkylation, and digestion for LC-MS/MS 
 
Protein reduction, alkylation, and digestion were carried out using a method previously 
published by the author [24]. Briefly, a 100 µg aliquot of protein sample was placed in a 
2 mL tube and dried by SpeedVac. The sample was reconstituted by 100 µL of lysis 
buffer (8 M urea, 10 mM DTT solution freshly prepared) and then adjusted to 200 µL by 
adding 100 µL of water. 200 µL of the reduction/alkylation cocktail consisted of 
triethylphosphine and iodoethanol was added to the protein solution. The sample was 
incubated at 35°C for 60 min, dried by SpeedVac, and reconstituted with 100 µL of 100 
mM NH4HCO3 at pH 8.0. A 150 µL aliquot of a 20 µg/mL trypsin solution was added to 
the sample and incubated at 35°C for 3 h, after which another 150 µL of trypsin was 
added, and the solution incubated at 35°C for 3 h. 
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2.3.3 LC-MS/MS analysis 
 
The digested samples were analyzed using a Thermo Scientific Orbitrap Velos Pro 
hybrid ion trap-Orbitrap mass spectrometer coupled with a Surveyor autosampler and 
MS HPLC system (Thermo Scientific). Tryptic peptides were injected onto a C18 
reversed phase column (TSKgel ODS-100V, 3 µm, 1.0 mm x 150 mm) at a flow rate of 
50 µL/min. The mobile phases A and B were LC-MS grade H2O with 0.1% formic acid 
and ACN with 0.1% formic acid, respectively. The gradient elution profile was as 
follows: 5% B for 6 min, 10-35% B for 156 min, 35-80% B for 10 min, and 80% B for 8 
min. The data were collected in the “Data dependent MS/MS” mode of FT-IT (MS-
MS/MS) with the ESI interface using normalized collision energy of 35% (CID). Dynamic 
exclusion settings were set to repeat count 1, repeat duration 30 s, exclusion duration 
120 s, and exclusion mass width 10 ppm (low) and 10 ppm (high). Each sample was 
injected twice. Raw data are available through PeptideAtlas with identifier PASS00645 
(http://www.peptideatlas.org/PASS/PASS00645). 
 
2.3.4 Protein identification and quantification 
 
The acquired data were searched against the UniProt protein sequence database of 
HUMAN (released on 02/19/2014) using X!Tandem algorithms in the Trans-Proteomic 
Pipeline (TPP, v. 4.6.3) (http://tools.proteomecenter.org/software.php). General 
parameters were set to:  parent monoisotopic mass error set as 10 ppm, cleavage semi 
set as yes, missed cleavage sites set at 2, and static modification set as + 44.026215 
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Da on Cysteine. The searched peptides and proteins were validated by PeptideProphet 
[25] and ProteinProphet [26] in TPP. Only proteins and peptides with protein probability 
≥ 0.9000 and peptide probability ≥ 0.8000 were reported. Protein quantification was 
performed using a label-free quantification software package, IdentiQuantXLTM [27]. 
Student’s t-test was used for the statistical analysis. 
 
2.4 Bioinformatics analysis 
 
In order to assign their subcellular locations, involvement in diseases and disorders, and 
network connectivity, proteins in each category were individually submitted to QIAGEN’s 
Ingenuity® Pathway Analysis (IPA®, QIAGEN Redwood City, ww.qiagen.com/ingenuity) 
in which the Ingenuity Pathways Knowledge Base is used. 
 
2.5 Immunohistochemistry  
 
The immunohistochemical staining was performed at Indiana University Health 
Pathology Laboratory according to a published method [28]. The process was carried 
out with an automated staining instrument Dako Autostainer Plus (Dako, Carpinteria, 
CA, USA) and its compatible detection kit EnVision™ FLEX+ Mouse (LINKER) (K8022, 
Dako, Carpinteria, CA, USA). Briefly, FFPE tissues (4 μm thickness) on slides were 
dried in an oven at 60°C for 20 min and deparafinized using xylene and graded alcohol 
in water for three times with the Tissue-Tek DRS 2000 automated stainer. Antigen 
retrieval was carried out by heating sections in EDTA (pH8.0) for 15 min with a pressure 
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cooker. Slides were cooled and rinsed in running water and placed in Envision Flex 
Wash Buffer until they were ready to load on the Autostainer Plus. Endogenous 
peroxidase activity was inactivated by incubation in 3% of H2O2 for 5 min. A periostin 
mouse monoclonal antihuman antibody (TA804575, OriGene Technologies, Inc., 
Rockville, MD, USA) was used as a primary antibody at 1:1000 dilution and incubated 
for 30 min at room temperature. EnVision™ FLEX+Mouse (LINKER) was used for signal 
amplification. EnVision™ FLEX/HRP detection reagent was applied for the coupling 
reaction. EnVision™ FLEX DAB+ Chromogen was utilized twice to produce a crisp 
brown endproduct at the site of the target antigen. EnVision™ FLEX Hematoxylin was 
employed for counterstaining to provide a nuclear staining in blue. The slides were then 
unloaded from the AutoStainer Plus and placed in the Tissue-Tek DRS stainer to 
dehydrate through graded alcohols and xylene. Lung adenocarcinoma was chosen as a 
positive control. Negative control was performed on enchondroma and chondrosarcoma 
tissue without adding the primary antibody. 
    The staining of periostin was scored according to percentage of positive staining in 
the whole section for each case (0 = no positive staining; 1 = 1%-25% positive; 2 = 
26%-50% positive; 3 = 51%-100% positive) and its intensity (0 = no staining, 1 = weak, 
2 = moderate, 3 = strong staining), as described previously [10, 17]. Because periostin 
locates in extracellular space, only extracellular matrix staining of atypical chondrocytes 
and/or stroma closely associated with tumor is considered a positive result. 
Immunostaining in normal bone marrow spaces should be considered negative. To 
assess periostin’s ability to distinguish low-grade chondrosarcoma from enchondroma, 
each stain was assigned either positive or negative for the clinical practice when the 
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sensitivity and specificity analyses were performed using XLSTAT (Addinsoft, New 
York, NY. http://www.xlstat.com/en/). 
 
3 Results 
 
3.1 Patient clinical information 
The clinical data of diagnosis, location, gender, and age at diagnosis of the 64 patients 
(38 females and 26 males; age range, 14-95 years old; mean, 49 years) are 
summarized in Supplemental Table 1. The 10 patients in Set 1 ranged in age between 
29 and 81 years old (mean, 49 years). Among the 23 low-grade chondrosarcoma and 
31 enchondroma tissue specimens in Set 2, the patients in low-grade chondrosarcoma 
group ranged in age from 27 to 95 years old (mean, 59 years). The male to female ratio 
was 14/9.  Patients in enchondroma group ranged in age from 14 to 71 years old 
(mean, 41 years). The male to female ratio was 9/22.  
 
3.2 Protein identification and quantification 
From the 20 injections, 489 protein groups (unique proteins) with a probability ≥ 0.9000 
were identified by 2,661 peptides with a probability ≥ 0.8000. The complete list of 
identified proteins is available in the Supplemental Table 2, where proteins identified 
with completely identical peptides are placed into a single protein group. None of decoy 
proteins was included in the list according to the probability cut-offs. Therefore, the false 
discovery rate is 0%. Among the 489 proteins, 347 proteins were identified with at least 
two distinct peptides. To obtain more accurate quantification, multiple filters were 
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applied to eliminate unqualified peptides for protein quantification [27]. The complete list 
of quantified proteins is available in the Supplemental Table 3, including 400 protein 
groups quantified by 1,834 peptides. Among them, 270 proteins were quantified with at 
least two distinct peptides. 
 
3.3 Bioinformatics analysis 
Besides subcellular locations, involvement in diseases and disorders proteins, and 
network connectivity, IPA provided important information, such as canonical pathways, 
upstream regulators, regulator effects, etc. To affiliate prioritization of the biomarker 
candidates, only the highly related results are presented in this publication. The network 
connectivity and subcellular location are presented in Figures 1-3. Among the 17 
proteins, 13 proteins exist in extracellular space. The involvement in diseases and 
disorders proteins of each protein is presented in Table 1. Almost all were involved with 
cancer except APOA4 and C1QB; 7 of the 17 proteins were related with connective 
tissue disorders. 
 
3.4 Immunohistochemistry  
Representative immunohistochemistry staining of periostin is presented in Figure 4 at 
400× original magnification including negative control, positive control, enchondroma, 
and low-grade chondrosarcoma. The stain scores for percentage and intensity of 
periostin in 23 low-grade chondrosarcoma and 31 enchondroma tissue samples are 
presented in the Supplemental Table 1 in detail. Among the 23 low-grade 
chondrosarcomas, 14 tissue samples were positively stained, while only 4 of the 31 
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enchondroma tissue samples were positively stained. The majority of positive cases 
showed strong and focal staining. The immunohistochemical staining for each sample of 
low-grade chondrosarcoma is presented in the Supplemental Figure 1. Calculated with 
XLSTAT, the specificity was 87% with a 95% confidence interval of 70-95% and the 
sensitivity was 70% with a 95% confidence interval of 49-84%. 
 
 
4 Discussion 
 
4.1 Principle to prioritize candidate proteins 
Once numerous proteins are identified and quantified in biomarker discovery phase, a 
challenging task is to determine which proteins should be chosen for further validation 
using alternative approaches. Simply by p value and/or fold change of a protein, the 
determination normally generates a long list of biomarker candidates. Therefore, it is a 
dilemma to decide which candidate has a better chance of success in validation and 
should be validated first since no unlimited source for validation is available. To resolve 
this problem, we categorize the candidates with different priorities according to couple 
the most critical factors and then rank the candidates inside each category based on 
multiple important factors.  
The aim of this study was to discover diagnostic biomarker candidates for clinical 
immunohistochemistry. Thus, the factors considered in candidate selection should be 
different from other approaches, such as concentration measurement in blood using 
ELISA or MRM (multiple reaction monitoring). An ideal biomarker should be positively 
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stained in low-grade chondrosarcoma tissue while negatively stained in enchondroma 
tissue; also, proteins commonly existing in blood are considered with lower priority than 
proteins not commonly present in blood. 
 
4.2 Factors in categorizing of protein candidates 
The first factor is the difference of protein identification frequency between low-grade 
chondrosarcoma and enchondroma tissues. Each group had five samples and each 
sample was injected twice. Therefore, 10 injections were analyzed for each group. If a 
protein was identified from every injection, its frequency is 1.0; if a protein was not 
identified from any injection, its frequency is 0.0. The detailed frequency of each protein 
is included in the Supplemental Table 2. Twenty-six proteins with a frequency difference 
between low-grade chondrosarcoma and enchondroma ≥ 0.4 were considered potential 
biomarker candidates. Excluding protein isoforms, 17 unique proteins were considered 
biomarker candidates. The frequency difference was used to determine candidacy. 
Also, the frequency difference was used to rank proteins in each biomarker candidate 
category (described as below). 
    The second factor is whether a protein commonly existed in blood or skin. Because 
residual blood could be present in the tissue samples, proteins from blood rather than 
the tissue cells would be identified as well. Although minimizing contamination has been 
performed in mass spectrometry experiments, dead skin cells still are present in lab 
environments. Keratins from skin are very often detected in proteomics [29]. However, 
these proteins should not be easily excluded from the candidate list, since they are 
usually expressed in multiple types of tissues and these proteins may be from blood 
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and/or the analyzed tissues. Therefore, keratins and common plasma proteins in the 
candidate list were labeled as Category 3, where proteins have lower priority in the 
candidate list for further validation. Among the 17 proteins, pigment epithelium-derived 
factor, apolipoprotein A-IV,  alpha-1B-glycoprotein, complement factor B, and 
complement C1q subcomponent subunit B are commonly detected in plasma or serum 
[30], Type II cytoskeletal 2 epidermal keratin is highly expressed in skin 
(http://www.genecards.org/cgi-bin/carddisp.pl?gene=KRT2#expression) and also highly 
detectable in plasma or serum [30]. 
The third concern is the protein identification frequency in enchondroma tissue. As 
mentioned above, our goal was to discover proteins positively stained in low-grade 
chondrosarcoma tissues while negatively stained in enchondroma tissues. If a protein 
was not identified in any of the enchondroma injections, it was considered a stronger 
candidate than a protein identified in some of the enchondroma injections. Based on 
this criterion, proteins with a frequency > 0 are put into Category 2, in which proteins 
have low priority for further validation. Other proteins are put into Category 1, in which 
proteins have high priority among the entire list.  
 
4.3 Criteria in ranking of candidate proteins inside categories 
Besides the frequency difference described above, the first criterion is the consistency 
between frequency difference and fold change. To further validate candidates 
discovered by proteomics, immunohistochemistry is applied. Because these analytical 
approaches have different sensitivity and reproducibility, selection of greater fold 
change values is more likely to insure successful biomarker detection across different 
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approaches. Fold change alone would serve well to rank the candidates when a protein 
is present in high abundance in one group (disease) but in low abundance or 
undetectable in the other group (control). When a protein has extremely low abundance 
in both groups, it is very often identified only in some injections of both groups or only 
identified in the disease group without detection in the control groups, potentially 
implying large fold difference between the two groups. However, the fold change is 
often not as large as expected or is sometimes very small due to detection limitation. 
Without using alternative and targeting analyses, such as MRM or ELISA, it is not 
possible to determine the real concentration. Under these circumstances, it is difficult to 
solely use fold change to determine the priority. On the contrary, if a protein’s fold 
difference is consistent with its frequency difference, this protein can be easily assigned 
with higher priority than other proteins whose fold difference are not consistent with their 
frequency difference.  The consistency is expressed as fold change × frequency 
difference. Higher score indicates higher priority. 
The second concern is the number of peptides used for protein identification. The 
more peptides used, the more confident the identification. Thus, a protein identified by 
multiple peptides has higher priority than a protein identified by a single peptide. Based 
on this criterion, proteins are further ranked inside the categories. 
The third factor is protein subcellular location. From a clinical immunohistochemistry 
aspect, nuclear proteins are easier to achieve a better immunohistochemistry stain than 
cytoplasm proteins, cytoplasm proteins are easier than plasma membrane proteins, and 
plasma membrane proteins are easier than extracellular proteins. Therefore, the 
assigned priority in each category is nuclear proteins > cytoplasm proteins > plasma 
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membrane proteins > extracellular proteins. In order to assign their cellular locations, 
proteins in each category were submitted to IPA. The software revealed that only 
AEBP1 locates in nucleus, PPIA in cytoplasm, MFI2 in plasma membrane, and all other 
proteins in extracellular space; KRT2 was the exception, since it was not assigned a 
specific location. To numerically show the importance and difference of each protein 
location, 10, 7, 4, 3, 1, and 0 are assigned to nucleus, cytoplasm, plasma membrane, 
extracellular space, and other (unknown or unassigned), respectively. 
The fourth factor is the protein’s relationship with targeted diseases and disorders. 
Because we were looking for biomarkers for chondrosarcoma, if a protein related to 
connective tissue disorders or cancer, it ranked higher than other proteins. A score was 
assigned to each related disease or disorder for the final calculation of priority. Proteins 
involved in connective tissue disorders were assigned 6 points; proteins related to 
cancer, 3 points; and proteins involved in both disorders, 9 points. IPA analysis was 
applied to identify the diseases or disorders in which each protein was involved. Among 
the 17 proteins, 15 were involved with cancer, except APOA4 and C1QB. Seven were 
related to connective tissue disorders (POSTN, TGFBI, SMOC2, SERPINF1, A1BG, 
C1QB, and CFB). 
 The fifth concern is protein connectivity in a network. To find potential links among 
the candidate proteins, IPA analysis is applied. IPA Networks are generated based on 
protein connectivity with other proteins. The more connected a protein is, the more 
important it is and the more influence it has. Therefore, the higher priority a protein is 
assigned, if a protein has more interconnection with other proteins in a network. When 
proteins in each category were submitted to IPA, a network was generated for each 
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category (Figures 1 - 3), indicating direct and indirect connectivity among some of the 
submitted proteins. The number of a protein’s connections in a network were counted. 
The more a protein has other proteins connected, the higher priority is assigned to the 
protein. 
 
4.4 Prioritization index of biomarker candidates for immunohistochemistry on 
tissue specimens (PIBIT)  
Multiple factors have been taken into account to rank biomarker candidates selected for 
immunohistochemical verification. One final score is needed to combine all the six 
factors. Four of these factors are numeric; i.e., frequency difference, consistency 
between frequency difference and fold change, number of peptides used for protein 
identification, and protein connectivity in a network. Protein subcellular location and the 
protein’s involvement in targeted diseases and disorders are not, but subsequently 
assigned numbers for the final score calculation. Finally, the individual score of each 
factor is combined in a formula and a signal score is reported to rank proteins in each 
category. 
    However, their weight in the calculation should be different. The frequency difference 
is recorded as a fraction. To normalize the importance of each factor, the weight of 
frequency difference is assigned as 10. The weight of the consistency between 
frequency difference and fold change is given 10 as well.  Therefore, the final score 
PIBIT was calculated using the following equation: 
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Where PIBIT = prioritization index of biomarker candidates for immunohistochemistry on 
tissue specimens, F0 = frequency difference × 10, F1 = consistency between frequency 
difference and fold change (fold change × frequency difference) × 10, F2 = number of 
peptides, F3 = subcellular location, F4 = involvement in targeted diseases and disorders, 
and F5 = connectivity in a network. According to the six factors, the PIBIT of each 
protein was calculated using the equation. All the factors and detail scores are listed in 
Table 1. Proteins are prioritized according to their PIBIT within each category.  
    The formula can be slightly modified to rank biomarker candidates for an assay when 
plasma/serum samples are used. The only change is the scoring of protein subcellular 
location. When immunohistochemistry is used to verify biomarker candidates for tissue 
samples, nuclear proteins have the highest score of 10 and extracellular proteins have a 
score of 1. On the contrary, when MRM or ELISA is applied to verify biomarker 
candidates for plasma/serum samples, 1, 3, 4, 7, 10, and 0 are assigned to nuclear 
proteins, cytoplasm proteins, plasma membrane proteins, extracellular proteins, and 
other (unknown or unassigned) proteins, respectively. To distinguish the PIBIT, this one 
is named as PIBAP, representing prioritization index of biomarker candidates for assay 
of plasma/serum specimens. 
    Furthermore, this idea can be more extensively applied to other projects whose 
factors are not identical to the factors discussed in this study, such as sensitivity, 
specificity, the area under the receiver operating characteristic (ROC) curve (AUC), etc. 
Basically, each factor and its weight have to be considered and then summed together. 
The single final score is simple but comprehensive, facilitating the priority determination. 
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4.5 Selection of periostin for immunohistochemistry verification 
Periostin’s discovery history, structure, isoforms, expression, functions, role in 
carcinogenesis and tumor progression-driving, and usage as a prognostic marker and 
novel therapeutic target have been summarized in a recent publication [31]. Periostin, 
also called osteoblast-specific factor 2, is an extracellular matrix protein involved in 
osteology, tissue repair, oncology, cardiovascular and respiratory systems, and in 
various inflammatory settings [32]. Periostin plays an important role in tumor 
progression in various types of cancer, including breast cancer, bladder cancer, colon 
cancer, non-small cell lung carcinoma, head and neck cancer, ovarian cancer, 
pancreatic ductal adenocarcinoma, melanoma, gastric cancer, oral squamous cell 
carcinoma, thymoma, and neuroblastoma [31, 33]. Noticeably, the upregulation of 
periostin in prostate, renal, and penile cancer was usually associated with a more 
aggressive tumor behavior and advanced stage, while it is weakly expressed in bladder 
cancer tissues [31]. Generally, it is known that its overexpression in cancer indicates the 
most malignant phenotypes and the poorest outcomes [34]. Periostin is preferentially 
expressed in the periosteum that covers a large majority of bones and is responsible for 
changes in bone diameter and cortical thickness [33]. It is expressed at a high level 
during embryogenesis and bone growth [33]. Periostin activates the Akt/PKB- and FAK-
mediated signaling pathways, leading to increased cell survival, angiogenesis, invasion, 
metastasis, and epithelial-mesenchymal transition of carcinoma cells [35]. Due to its 
roles in tumor development, periostin has been speculated as a therapeutic and 
diagnostic target for cancer [36]. According to the proteomics results and the literature, 
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periostin is a highly preferred biomarker candidate for further validation. Therefore, 
periostin was chosen as the first one for verification by immunohistochemistry. 
 
4.6 Other proteins in the category 1 
There are six other proteins (TGFBI, AEBP1, PCOLCE, SMOC2, MFI2, CPXM2) listed 
in the Category 1. TGFBI mediates cell adhesion to extracellular proteins such as 
collagen, fibronectin and laminins through integrin binding. It is overexpressed in 
several solid tumors including colon, pancreas, and kidney [37]. AEBP1 has been 
reported to be upregulated in stroma of mammary tumors and breast cancer cells [38]. 
PCOLCE stimulates procollagen processing by procollagen C-proteinases and is 
involved in tumor growth, neurodegenerative diseases, and angiogenesis [39]. SMOC2 
enhances the angiogenic effect of basic fibroblast growth factor and vascular 
endothelial growth factor, mediates mitogenesis in mouse fibroblasts, interacts with 
vitronectin and cell surface receptors of the integrin family. Moreover, it affects the 
migration of keratinocytes, the process of metastasis, and pulmonary function [40]. 
Melanotransferrin is expressed at low levels in normal adult tissues, but at high levels in 
melanoma tumors, other cancers, and foetal tissues [41]. CPXM2 is a member of the 
metallocarboxypeptidase gene family and identified from its homology with 
carboxypeptidase E [42]. It is upregulated in fetal growth restriction [43]. All six were 
identified with multiple peptides and involved in cancer. TGFBI and SMOC2 are related 
with connective tissue disorders. This information suggests that the six proteins are 
good candidates for further biomarker validation. 
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4.7 Proteins not in the category 1 
There are 10 more proteins not in the Category 1 of biomarker candidates. Some have 
a high PIBIT score, such as decorin and pigment epithelium-derived factor. Decorin is a 
component of connective tissue and locates at cellular or pericellular matrix. It has 
become a focus in various areas of cancer research [44]. Decorin has been involved in 
various biological processes, such as collagen fibrillogenesis, wound healing, 
myogenesis, stem cell biology, and fibrosis [45]. Pigment epithelium-derived factor is a 
serine protease inhibitor and has been detected in multiple tissues including brain, 
spinal cord, liver, bone, eye, heart, lung and plasma [46]. It has been reported to be a 
potent angiogenic inhibitor to prevent angiogenesis and metastasis, induce tumor cell 
apoptosis, and prevent cancer cell growth in a range of cancers, such as osteosarcoma, 
chondrosarcoma, lung, breast, and prostate cancer [47]. Although these proteins are 
not in the Category 1 of prioritization, they are still valuable biomarker candidates. The 
category and prioritization are only intended to validate the protein candidates in a 
quicker and less expensive way by validating candidates who have the best chance of 
success in validation. 
The objective of this research was to discover diagnostic biomarker candidates for 
clinical immunohistochemistry to distinguish benign (enchondroma) from low-grade 
chondrosarcoma. The diagnosis is one of the most frequent diagnostic dilemmas in 
clinical management facing orthopedic oncologists. As a result of the comprehensive 
mass spectrometry-based analysis used in this study, we have identified 17 biomarker 
candidates. The best candidate, periostin, was verified with immunohistochemistry on 
23 low-grade chondrosarcoma and 31 enchondroma tissue samples, indicating 
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sensitivity 70% and specificity 87%. Although it does not yet meet the 90/90 standard, 
better reliable diagnostic immunohistochemistry markers have not yet been identified 
and verified. Validation of other biomarker candidates in a follow-up study will facilitate 
establishment of reliable immunohistochemical methods. 
 
The authors have declared no conflict of interest. 
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Figure Legends 
 
Figure 1. All seven proteins in Category 1 submitted to IPA are included in the 
generated network. Top diseases and functions involved in the network include tissue 
morphology, connective tissue disorders, and hereditary disorder. One protein locates in 
nucleus, one exists in plasma membrane, and all others are present in extracelluar 
space. POSTIN has the most network connectivity. 
 
Figure 2. Among the five proteins in Category 2 analyzed with IPA, four proteins are 
included in the network. Cellular movement, hematological system development and 
function, and immune cell trafficking are the top three involved diseases and functions. 
Only PPIA locates in cytoplasm. The other three proteins all exist in extracelluar space. 
DCN has the most network connectivity. 
 
Figure 3. All six proteins in Category 3 submitted to IPA are included the generated 
network. The top three 3 diseases and functions involved in the network are lipid 
metabolism, small molecule biochemistry, and molecular transport. All six proteins all 
are present in extracellular space. APOA4 has the most network connectivity. 
 
Figure 4. Immunohistochemical staining for periostin of negative control, positive 
control, enchondroma, and low-grade chondrosarcoma (original magnification ×400). 
Periostin locates in extralcellular space. Therefore, the matrix staining pattern is 
observed. 
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Table 
Table 1. The ranking and categorizing of protein biomarker candidates with a frequency 
difference ≥ 0.4.  
R C ID GN PFE PFC FD FC #P 
SL ITDD 
NC PIBIT NM SC CS CTS TS 
1 1 B1ALD8 POSTN 0 0.8 0.8 8.3 5 E 1 3 6 9 14 103.4 
2 1 G8JLA8 TGFBI 0 0.6 0.6 2.7 8 E 1 3 6 9 5 45.2 
3 1 Q8IUX7 AEBP1 0 0.6 0.6 1.1 6 N 10 3 0 3 5 36.6 
4 1 Q15113 PCOLCE 0 0.6 0.6 1.6 5 E 1 3 0 3 8 32.6 
5 1 Q9H3U7 SMOC2 0 0.4 0.4 2.8 2 E 1 3 6 9 2 29.2 
6 1 P08582 MFI2 0 0.4 0.4 2.3 5 P 4 3 0 3 1 26.2 
7 1 Q8N436 CPXM2 0 0.6 0.6 1.6 4 E 1 3 0 3 1 24.6 
8 2 P07585 DCN 0.5 1.0 0.5 2.4 10 E 1 3 0 3 19 50.0 
9 2 P62937 PPIA 0.2 0.6 0.4 -1.0 5 C 7 3 0 3 8 23.0 
10 2 P07093 SERPINE2 0.3 1.0 0.7 -1.1 10 E 1 3 0 3 9 22.3 
11 2 Q16674 MIA 0.3 0.7 0.4 1.0 1 E 1 3 0 3 2 15.0 
12 3 P36955 SERPINF1 0.4 0.8 0.4 1.6 12 E 1 3 6 9 7 39.4 
13 3 P06727 APOA4 0.2 0.7 0.5 1.1 6 E 1 0 0 0 15 32.5 
14 3 P04217 A1BG 0 0.4 0.4 1.8 5 E 1 3 6 9 2 28.2 
15 3 B4E1Z4 CFB 0 0.4 0.4 1.2 3 E 1 3 6 9 6 27.8 
16 3 D6R934 C1QB 0.4 0.8 0.4 1.0 7 E 1 0 6 6 3 25.0 
17 3 P35908 KRT2 0.5 0.9 0.4 1.3 5 O 0 3 0 3 1 18.2 
Note: R, Rank; C, Category; ID, Protein ID; GN, Gene Name; PFE, Protein identification 
frequency in enchondroma tissues; PFC, Protein identification frequency in low-grade 
chondrosarcoma tissues; FD, Difference of protein identification frequency between low-
grade chondrosarcoma and enchondroma tissues. FC, Fold change; #P, Number of 
peptides; SL, Subcellular location; NM, Name of the subcellular location, including N for 
nucleus, C for cytoplasma, P for plasma membrane, E for extracellular space, and O for 
other; SC, Score of the subcellular location; ITDD, Involvement in targeted diseases and 
disorders; CS, Cancer score of the involvement in targeted diseases and disorders; 
CTS, Connective tissue disorder score of the involvement in targeted diseases and 
disorders; TS, Total score of the involvement in targeted diseases and disorders; NC, 
Network connectivity; and PIBIT, Prioritization index of biomarker candidates for 
immunohistochemistry on tissue specimens. The PIBIT is calculated using a formula of 
FD × 10 + FD × FC × 10 + #P + SC + TS + NC. 
 
 
